At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Midazolam +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Fixed-Sequence Study to Evaluate the Effect of Multiple Doses of LOXO-292 on the Single Dose Pharmacokinetics of Midazolam in Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating Midazolam and Selpercatinib for Healthy. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The main purpose of this study is to assess the effect of selpercatinib on how fast midazolam gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to about 6 weeks, inclusive of screening period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsLoxo Oncology, Inc.
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartJul 2018
Primary CompletionAug 2018
Study CompletionSep 2018
First PostedApr 2022
TodayJul 2026
First PostedApr 21, 2022
Enrollment StartJul 12, 2018
Primary CompletionAug 1, 2018
Study CompletionSep 18, 2018
TodayJul 2, 2026
Enrollment to primary: 19 daysPosted 4.2 years ago
Interventions
Midazolamdrug
Administered orally.
Selpercatinibdrug
Administered orally.